Displaying drugs 276 - 300 of 554 in total
Tosedostat
Tosedostat has been used in trials studying the treatment and supportive care of AML, Leukemia, Pancreas Cancer, Multiple Myeloma, and Pancreatic Cancer, among others.
Tosedostat is an inhibitor of the M1 family of aminopeptidases, in particular PuSA, and LTA4 hydrolase. It has demonstrated anti-tumour activity in a number of models...
Investigational
ADH-1
Adherex's biotechnology compound, ADH-1, targets N-cadherin, a protein present on certain tumor cells and established tumor blood vessels. ADH-1 is currently in clinical development in a combination program with a range of chemotherapeutic agents to investigate the synergistic effects noted in our preclinical models. At the end of 2006, the...
Investigational
Matched Description: … and established tumor blood vessels. ... causing angiolysis (disruption of blood vessels) and tumor damage. ... Adherex's biotechnology compound, ADH-1, targets N-cadherin, a protein present on certain tumor cells …
GVAX
GVAX is a granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transfected tumor cell vaccine.
Investigational
Matched Description: … GVAX is a granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transfected tumor cell vaccine …
Zafiride
Zafiride is a human tumor necrosis factor coupled to the C terminus of CNGRCG peptide.
Investigational
Matched Description: … Zafiride is a human tumor necrosis factor coupled to the C terminus of CNGRCG peptide. …
PTC299
PTC299 is a novel, orally administered small-molecule designed to inhibit the production of vascular endothelial growth factor (VEGF) in tumors. Overexpression of VEGF plays a key role in multiple diseases including cancer and macular degeneration. PTC299 was discovered through PTC's GEMS technology by targeting the post-transcriptional processes that regulate VEGF...
Investigational
Zebularine
A chemically stable, cytidine analog that displays anti-tumor properties. It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as covalent hydrates. Also shown to inhibit DNA methylation and tumor growth both in vitro and in vivo.
Experimental
Matched Description: … A chemically stable, cytidine analog that displays anti-tumor properties. ... Also shown to inhibit DNA methylation and tumor growth both in vitro and in vivo. …
Safingol
Safingol has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Matched Description: … Safingol has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific …
Bizelesin
Bizelesin has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Matched Description: … Bizelesin has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific …
Timcodar
Timcodar has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Matched Description: … Timcodar has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific …
Crolibulin
Crolibulin has been used in trials studying the treatment of Solid Tumor and Anaplastic Thyroid Cancer.
Investigational
Matched Description: … Crolibulin has been used in trials studying the treatment of Solid Tumor and Anaplastic Thyroid Cancer …
GDC-0349
GDC-0349 has been used in trials studying the treatment of Non-Hodgkin's Lymphoma, Solid Tumor.
Investigational
Matched Description: … GDC-0349 has been used in trials studying the treatment of Non-Hodgkin's Lymphoma, Solid Tumor. …
Tengonermin
Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. This drug works by modifying the tumor microenvironment and increasing intratumoral chemotherapy penetration and T-cell infiltration. NGR-hTNF specifically targets angiogenic...
Investigational
Matched Description: … [A233265]
NGR-hTNF specifically targets angiogenic tumor blood vessels using the NGR motif. ... [L33050] This drug works by modifying the tumor microenvironment and increasing intratumoral chemotherapy ... Literature demonstrates that NGR-peptides bind to a CD13 isoform, of which expression is restricted to tumor …
AEG35156
A second-generation synthetic antisense oligonucleotide with potential antineoplastic activity. AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors. This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs to overcome...
Investigational
Matched Description: … to overcome tumor cell resistance to apoptosis. ... This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs ... interferes with both the intrinsic and extrinsic program-death signaling pathways, which may render tumor …
FavId
FavId, is an active immunotherapy that is based upon unique genetic information extracted from a patient's tumor.
Investigational
Matched Description: … is an active immunotherapy that is based upon unique genetic information extracted from a patient's tumor …
BMS-188797
BMS-188797 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Matched Description: … BMS-188797 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol …
CHS-828
CHS-828 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Matched Description: … CHS-828 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific …
XL765
XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). It is being developed by Exelixis, Inc.
Investigational
AVX-470
AVX-470 is an anti-tumor necrosis factor (TNF) polyclonal antibody (bovine).
Investigational
Matched Description: … AVX-470 is an anti-tumor necrosis factor (TNF) polyclonal antibody (bovine). …
MT-401
MT-401 is an allogeneic multi-tumor-associated antigen-specific T-cell therapy.
Investigational
Matched Description: … MT-401 is an allogeneic multi-tumor-associated antigen-specific T-cell therapy. …
Denibulin
Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.
Investigational
Matched Description: … novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor …
Labetuzumab
Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy.
Investigational
Matched Description: … Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth …
Apomine
Apomine has been used in trials studying the treatment of Osteoporosis and Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Matched Description: … Apomine has been used in trials studying the treatment of Osteoporosis and Unspecified Adult Solid Tumor …
Motexafin gadolinium
Motexafin gadolinium is studied in the treatment of cancer by Pharmacyclics. It may make tumor cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and kill cancer cells. It belongs to the family of drugs called metalloporphyrin complexes. Also called gadolinium texaphyrin.
Investigational
Matched Description: … It may make tumor cells more sensitive to radiation therapy, improve tumor images using magnetic resonance …
MK-1454
A synthetic cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING), with potential immunoactivating and antineoplastic activities. Upon intratumoral (IT) administration, STING agonist MK-1454 binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB)...
Investigational
Matched Description: … This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. ... Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens ... activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor …
Oregovomab
Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.
Investigational
Matched Description: … Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125. …
Displaying drugs 276 - 300 of 554 in total